PT - JOURNAL ARTICLE AU - Ricardo Zaragoza AU - Daniel Miulli AU - Samir Kashyap AU - Tyler A Carson AU - Andre Obenaus AU - Javed Siddiqi AU - Douglas W Ethell TI - Impairment of CSF Egress through the Cribriform Plate plays an Apical role in Alzheimer’s disease Etiology AID - 10.1101/2021.10.04.21264049 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.04.21264049 4099 - http://medrxiv.org/content/early/2021/10/05/2021.10.04.21264049.short 4100 - http://medrxiv.org/content/early/2021/10/05/2021.10.04.21264049.full AB - Cerebrospinal fluid (CSF) clears the brain’s interstitial spaces, and disruptions in CSF flow or egress impact homeostasis, contributing to various neurological conditions. Here, we recast the human cribriform plate from innocuous bony structure to complex regulator of CSF egress with an apical role in Alzheimer’s disease etiology. It includes the pathological evaluation of 70 post-mortem samples using high-resolution contrast-enhanced micro-CT and cutting-edge machine learning, a novel ferret model of neurodegeneration, and a clinical study with 560 volunteers, to provide conclusive evidence of a relationship between cribriform plate aging/pathology and cognitive impairment. Interstitial spaces within the medial temporal lobe and basal forebrain are cleared by CSF flow that drains through olfactory structures to the olfactory bulb—directly above the cribriform plate. We characterized CSF flow channels from subarachnoid spaces under the olfactory bulb to the nasal mucosa through subarachnoid evaginations that subdivide into tiny tubules that connect to an elaborate conduit system within the cribriform plate. These conduits form an internal watershed that runs from the crista galli’s vault to a bony manifold within the olfactory fossa’s back wall, connecting with large apertures in between. We found that the cross-sectional area of apertures limits CSF flux through the cribriform plate, which declines with increasing age. Subjects with a confirmed post-mortem diagnosis of Alzheimer’s disease had the smallest CSF flux capacity, which reduces CSF-mediated clearance in upstream areas and leads to the accumulation of toxic macromolecules that seen AD pathology. We surgically occluded apertures in adult ferrets and found that this manipulation induced progressive deficits in spatiotemporal memory and significant atrophy of the temporal lobe, olfactory bulbs, and lateral olfactory stria. Finally, we explored human cribriform plate aging/pathology and cognition in a clinical study with 560 participants (20-95y). We evaluated cribriform plate morphology with CT and Deep Learning, assessed memory with a novel touch screen platform, tested olfactory discrimination, and asked questions about family history and relevant life events, like broken noses. Deep learning algorithms effectively parsed subjects and established the feasibility of predicting Alzheimer’s disease years before a clinical presentation of cognitive impairment. This study provides a new perspective of the cribriform plate as a critical regulator of CSF egress and brain homeostasis.Competing Interest StatementDE, RZ, DM, and JS hold equity in Leucadia Therapeutics. AO, SK, and TC declare no competing interestsClinical TrialClinical data collected was observational and non-interventional.Funding StatementFunding was provided Methuselah Foundation and Leucadia Therapeutics Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:An observational clinical study was done under an IRB protocol approved by the Arrowhead Regional Medical Center IRB Committee. An IRB to harvest and study human cribriform plate tissue samples was approved by the Western University of Health Sciences IRB Committee. An animal study was done under an approved IACUC protocol from Loma Linda University's IACUC Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant data and information are provided in the supplementary information.